- Home
- / Pernix Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Pernix Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$887.8
2020-04-29
Market Capitalization
$3 M
2019-03-04
Revenue
$146.1 M
FY, 2017
CreditSafe Score
?
Score changed on Jul 24, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 60.6M | 61.3M | 84.9M | 121.7M | 175.9M | 140.9M | 146.1M |
| Revenue growth, % | 43.4% | 44.4% | |||||
| Cost of goods sold | 20.5M | 23.4M | 43.9M | 45.2M | 51.4M | 43.3M | 44.6M |
| Gross profit | 40.1M | 37.9M | 41.0M | 76.6M | 124.4M | 97.5M | 101.4M |
| Gross profit margin, % | 66.1% | 61.9% | 48.3% | 62.9% | 70.8% | 69.2% | 69.4% |
| General and administrative expense | 22.5M | 35.5M | 62.6M | 63.0M | 97.4M | 98.8M | 76.8M |
| Operating expense total | 27.0M | 39.6M | 62.6M | 63.0M | 97.4M | 237.9M | 157.9M |
| Depreciation and amortization | 86.1M | 73.2M | |||||
| EBIT | 13.1M | (1.7M) | (54.7M) | (30.2M) | (101.3M) | (140.3M) | (56.5M) |
| EBIT margin, % | 21.6% | -2.8% | -64.4% | -24.8% | -57.6% | -99.6% | -38.7% |
| Interest expense | 171.4K | 94.8K | 4.0M | 18.8M | 38.3M | ||
| Pre tax profit | (46.4M) | (49.0M) | (141.3M) | (169.2M) | (76.8M) | ||
| Income tax expense | 4.6M | (374.0K) | (20.8M) | (13.7M) | 7.1M | 439.0K | 373.0K |
| Net Income | 8.3M | (1.4M) | (25.6M) | (35.3M) | (148.3M) | (169.6M) | (77.1M) |